Institute for Safe Medication Practices (ISMP), 2017-04-06: ISMP safety alert reporting that a methylene blue shortage in 2017 forced a hospital to switch from its usual generic product to brand ProvayBlue, the newly FDA-approved product.
Due to the current drug shortage of methylene blue, a hospital switched from the generic product it normally used to the brand product PROVAYBLUE, which the US Food and Drug Administration (FDA) approved last year.
p. 1
Institute for Safe Medication Practices (ISMP), 2017-04-06: ISMP safety alert reporting that a methylene blue shortage in 2017 forced a hospital to switch from its usual generic product to brand ProvayBlue, the newly FDA-approved product. C2 availability after approval. One hospital's experience; error case (ProvayBlue compounded in 0.9% sodium chloride, precipitate formed, no patient harm). Documents that the approved brand product entered use during a shortage of the generic. text_file=A_12.txt Study type: other.
